SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending due to its strategic partnership with Palantir and World View to develop AI-enabled multi-domain intelligence and defense systems, a move seen as highly transformative by the community alongside recent defense tech acquisitions. While many investors are bullish on the company's long-term potential and anticipate a short squeeze, others are expressing concerns over share dilution and the stock's struggle to maintain gains.

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Incannex Healthcare Limited - ADR

Incannex Healthcare (IXHL) is experiencing a notable rally driven by impending NASDAQ compliance and heightened speculation regarding positive FDA End-of-Phase 2 results for its Fast Track designated sleep apnea drug, IHL-42X, with its low share float further amplifying short squeeze potential among traders.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is actively discussed following multiple strategic announcements, including a sovereign AI architecture with NVIDIA and expanded partnerships in defense, energy, and commercial AI. The community is highly enthusiastic, viewing these collaborations as strong validation of Palantir's AI platform and its crucial role across diverse, high-stakes sectors.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending after reporting a beat on earnings and achieving its first GAAP profitable year, complemented by a new $500M share buyback; however, its conservative forward guidance and subsequent analyst downgrades have fueled a community debate between bullish long-term conviction in agentic AI leadership and concerns over decelerating growth.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending after securing pivotal Japanese marketing approval for its Alpha DaRT technology, a massive de-risking event that has analysts raising price targets while the community asserts these valuations are still significantly undervalued given the company's strong cash position and promising oncology pipeline.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is trending due to a new development agreement with Tower Semiconductor to integrate its electro-optic polymer modulators into Tower's silicon photonics platform. The market views this as significant validation, fueling discussions about its role in future AI infrastructure and the long-term potential of its technology, despite ongoing volatility and profit-taking.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending following the successful launch of its Alpha Flight 7 mission, which delivered a Lockheed Martin payload into orbit, marking a crucial comeback for the Alpha rocket program and driving positive community sentiment in the competitive commercial space sector.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending due to escalating tanker attacks and critical supply disruptions in the Strait of Hormuz, driving strong community debate over whether substantial strategic reserve releases can mitigate the sustained geopolitical risk or if oil prices are poised for further significant volatility.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its community, fueled by strong conviction, relentlessly promotes the token's "OG Meme" status and authenticity as a Solana-based project, aiming for significant market cap expansion. The community emphasizes consistent engagement and 'bagworking' while encouraging others to join and avoid "fake" tokens.

Dollar General Corp. engages in the operation of merchandise stores. Its offerings include food, snacks, health and beauty aids, cleaning supplies, basic apparel, housewares, and seasonal items. It sells brands including Clorox, Energizer, Procter & Gamble, Hanes, Coca-Cola, Mars, Unilever, Nestle, Kimberly-Clark, Kellogg's, General Mills, and PepsiCo. The company was founded by J. L. Turner and Hurley Calister Turner Sr. in 1939 and is headquartered in Goodlettsville, TN.

Dollar General Corp.

Dollar General is trending following its robust earnings report, which surpassed expectations and included upbeat fiscal guidance and significant expansion plans. The community is split, with some questioning the immediate market reaction despite the strong results, while others highlight its appeal as a value-driven retailer benefiting from cautious consumer spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

<ul class="summary-bullets"><li>The company also secured a private placement financing worth around $200 million.</li><li>Sensei Biotherapeutics plans to use the majority of the proceeds to advance PIKTOR.</li><li>Remaining funds will be used for the development of Sensei’s Phase 1/2 trial candidate, Solnerstotug.</li></ul>Shares of Sensei Biotherapeutics (SNSE) shot up over 200% on Wednesday after the company strengthened its oncology pipeline by announcing the acquisition of Faeth Therapeutics.<a href="https://stocktwits.com/symbol/SNSE">SNSE stock</a> rose to its highest since May 2024 and recorded its biggest-ever intraday gains. Trading in the stock was twice halted after the opening bell, according to Nasdaq data.The acquisition adds Faeth’s lead investigational therapy, PIKTOR, an all-oral drug combination that targets tumor metabolism and blocks multiple points in the PI3K/AKT/mTOR pathway, a critical cell signaling system that regulates cell survival, growth, and division.“In the PI3K pathway, the field has repeatedly run into the same constraint. Single-node inhibitors force a tradeoff between efficacy and tolerability. PIKTOR is designed to change that tradeoff by inhibiting PI3K-alpha and mTORC1/2 simultaneously, and we believe we can achieve more complete pathway suppression with improved tolerability,” said Anand Parikh, Co-founder of Faeth Therapeutics and the new COO and director of Sensei.<h2 class="st-heading-2">$200 Million Private Placement</h2>Sensei Biotherapeutics also secured private placement financing, worth about $200 million. The company plans to use most of the capital to advance PIKTOR, including topline results from an ongoing Phase 2 trial in second-line advanced endometrial cancer and the launch of a Phase 1b study in HR+/HER2- advanced breast cancer, both anticipated by the end of 2026.Remaining funds will support general corporate initiatives and the continued development of Sensei’s Phase 1/2 trial candidate, Solnerstotug.The private placement attracted participation from B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, and Vivo Capital, among other life sciences funds and institutional investors.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish,’ amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/SNSE_jpg_53f7157d12.webp" alt="SNSE.jpg">One user expects the stock to “go up big” if it holds above the $25.4 to $25.5 support. It is currently trading at around $28.<stembedurl>https://stocktwits.com/brewstocks123/message/645236001</stembedurl>Another user expects the stock to climb to $44 by the end of the session.<stembedurl>https://stocktwits.com/FreyBentos/message/645238839</stembedurl>The stock has gained around 160% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rxt-stock-soars-pre-market-palantir-connection/cZR0r6BR4vX">RXT Stock Soared 275% Today – What’s The Connection&nbsp;With Palantir?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Representative image of a trending stock chart.

 SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition

Shares of Sensei Biotherapeutics (SNSE) shot up over 200% on Wednesday after the company strengthened its oncology pipeline by announcing the acquisition of Faeth Therapeutics.

Equity

The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.

<ul class="summary-bullets"><li>The data showed that patients treated with ELEVIDYS experienced a significant and durable slowing of disease progression compared with an external control group.</li><li>ELEVIDYS reduced the rate of functional decline by about 70%.</li><li>ELEVIDYS has been administered to more than 1,200 patients worldwide in both clinical trials and real-world use.</li></ul>Shares of Sarepta Therapeutics (SRPT) jumped 6% in pre-market trading on Monday after the company announced positive three-year topline results from its Phase 3 EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with Duchenne Muscular Dystrophy (DMD).SRPT shares gained further after the opening bell, trading 12% higher at the time of writing.The data showed that patients treated with ELEVIDYS experienced a significant and durable slowing of disease progression compared with an external control group. Three years after treatment, patients maintained North Star Ambulatory Assessment (NSAA) scores above baseline, while untreated patients showed the expected decline.ELEVIDYS reduced the rate of functional decline by about 70% or more on key measures, including Time to Rise and the 10-meter walk/run, with the treatment effect increasing over time. No new safety concerns were identified, supporting ELEVIDYS’ manageable safety profile.Sarepta said analysis of its three-year data is ongoing and includes functional results from patients who crossed over to treatment and have now been followed for two years.&nbsp;ELEVIDYS is currently the only approved gene therapy for DMD and has been given to more than 1,200 patients worldwide in both clinical trials and real-world use. The therapy is available for ambulatory patients aged four and older under an updated FDA label announced in late 2025.&nbsp;<h2 class="st-heading-2">Latest Updates</h2>Sarepta is working with Roche to broaden global access to the therapy, with Sarepta handling U.S. regulatory approval, manufacturing, and commercialization, and Roche managing approvals and distribution outside the United States.Earlier this month, the company announced the submission of a clinical trial application to New Zealand’s Medsafe for its INSIGHTT study of SRP-1005, an investigational small interfering RNA (siRNA) therapy for Huntington’s disease. If approved, the first-in-human trial is expected to begin in the second quarter of 2026.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ amid ‘extremely high’ message volumes. <a href="https://stocktwits.com/symbol/SRPT">SRPT</a> was among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/srpt_jpg_4e3ede4352.webp" alt="srpt.jpg">One bullish user said the ‘results are very impressive for a rare disease with no cure’.<stembedurl>https://stocktwits.com/free2dream/message/642864936</stembedurl>Another user added that breaking the $25 resistance mark would be huge. The stock is currently trading around $23.5.<stembedurl>https://stocktwits.com/Sareptaking/message/642878594</stembedurl>The stock has been under heavy selling pressure over the past year, declining more than 80%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/traw-stock-slides-in-volatile-session-after-covid-19-treatment-trial-update/cmy7u2BR4hI">TRAW Stock Slides In Volatile Session –&nbsp; What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Did SRPT Stock Rise 6% In Pre-Market Today?

The company announced positive three-year topline results from its EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with DMD.   

SRPT Pre-Market Rally Fueled By Promising DMD Therapy Results

The company announced positive three-year topline results from its EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with DMD.

 

<ul class="summary-bullets"><li>Shiong added that “median overall survival” is a scientific endpoint that is used to measure survival, which currently stands at six months for patients with brain tumors.</li><li>Explaining what this means, he said that half of the patients at this stage do not survive beyond six months.</li><li>The Culver City, California-based immunotherapy company stated in an update on Friday that it had not yet achieved median survival among patients receiving Anktiva + CAR-NK in the trial.</li></ul>ImmunityBio Inc. (IBRX) shares were up more than 5% in Monday’s pre-market trade after a volatile session on Friday following the company’s Phase 2 glioblastoma trial update.The Culver City, California-based immunotherapy company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-volatility-after-immunitybio-phase-2-glioblastoma-trial-update/cmyR7VnR4gk">stated</a> in an update on Friday that it had not yet achieved median survival among patients receiving Anktiva + CAR-NK in the trial. The company said that as of Jan. 22, 2026, it had enrolled 23 patients in the Phase 2 glioblastoma trial, of which four deaths have been reported so far, while 14 patients have evaluable clinical data.<h2 class="st-heading-2">ImmunityBio Founder Issues Clarification</h2>However, Patrick Soon Shiong, ImmunityBio’s founder,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2015148449059201385">took</a> to X on Saturday to clarify what the update signified.“The fact that we have patients alive still at 12 months and that the ‘median has NOT YET&nbsp; been reached’ IS a positive and promising finding to date with our chemo free treatment in which patients have failed current standards of care,” he said.He added that “median overall survival” is a scientific endpoint that is used to measure survival, which currently stands at six months for patients with brain tumors. Explaining what this means, he said that half of the patients at this stage do not survive beyond the timeframe of six months or longer.<figure class="image"><img src="https://news.stocktwits-cdn.com/Patrick_post_jpg_65b0607bff.webp" alt="Dr. Pat Soon-Shiong's post on X" width="727" height="500"><figcaption>Dr. Pat Soon-Shiong's post on X | @DrPatrick/X</figcaption></figure><h2 class="st-heading-2">How Stocktwits Users Reacted</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio</a> was in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One bullish user said that they believe IBRX should trade at a market capitalization of $10 billion, while adding that ImmunityBio represents a “complete shift in standard of care of cancer.” The company’s current market capitalization is $6.35 billion.<stembedurl>https://stocktwits.com/BixbyKnolls/message/642850960</stembedurl>Another user wondered why any investor would not hold the IBRX stock with “so many approvals on the horizon.”<stembedurl>https://stocktwits.com/Nate711/message/642846497</stembedurl><a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> is up 226% year-to-date and 107% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/peter-schiff-silver-gold-price-rally-people-clueless-slv-gld-etf-soar-pre-market/cmy7FWpR4Wx">Peter Schiff Says Most People Are 'Clueless' And In For A 'Shock' As Gold, Silver Scale New Highs: SLV, GLD ETFs Soar Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research

Patrick Soon Shiong, ImmunityBio’s founder, took to X on Saturday to clarify what the update signified.

<ul class="summary-bullets"><li>The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</li><li>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment.</li><li>Test volumes climbed to 18,000 in Q4 and 62,600 for the year.</li></ul>Biodesix Inc. (BDSX) stock surged over 23% in Monday’s premarket after the Colorado-based diagnostics firm provided a strong outlook for the fourth quarter (Q4) and fiscal year 2025.&nbsp;The company expects Q4 revenue of $28.8 million, a 41% year-over-year (YoY) increase, while full-year revenue is estimated at $88.5 million, up 24% YoY. The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Growth Driven By Lung Diagnostics</h2>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment, which is estimated to have generated $25.2 million in Q4 and $79.2 million for the full year. The results reflect a 47% and 22% YoY increase, respectively.&nbsp;Test volumes climbed to 18,000 in Q4 and 62,600 for the year, rising 23% and 15% from the previous year. The increase was driven by higher test volumes, stronger revenue per test, and about $1 million in collections from older claims.&nbsp;<blockquote>“Biodesix finished 2025 with a strong fourth quarter, delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million.”-Scott Hutton, CEO, Biodesix</blockquote>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/BDSX">Biodesix stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_12_084117_png_27b632f1b5.webp" alt="BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits" width="931" height="98"><figcaption>BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Development Services&nbsp;</h2>The company’s development services segment contributed an estimated $3.6 million in Q4 and $9.3 million for 2025, representing growth of 13% and 41% over the prior year, respectively.&nbsp;“Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter,” added Hutton.&nbsp;Biodesix said it ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase over the previous quarter.&nbsp;BDSX stock declined by over 77% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-captures-20-of-global-smartphone-market/cmU96DMR4E4">Apple Captures 20% Of Global Smartphone Market, But Rising Memory Costs Cast Shadow On 2026 Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biodesix logo is seen displayed on a smartphone screen.

BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? 

The company expects Q4 revenue of $28.8 million, a 41% year-over-year increase, while full-year revenue is estimated at $88.5 million, up 24% year-over-year.

This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why 

Inside the Recent Strength in Biotech ETFs 

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.



2 ETFs to Watch for Outsized Volume on Biotechnology Stocks 

Biotech ETFs PBE and FBT saw trading volumes soar to over four times their averages, signaling rising interest amid a down day for major indexes.  

FBT
First Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund

Feed

News

Sentiment

Fundamentals

Info

Latest FBT News

FBTFirst Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund